Clinical outcomes of combined Preserflo Microshunt implantation and cataract surgery in open-angle glaucoma patients

Abstract To assess the effectiveness and safety of the Preserflo Microshunt (PMS) implantation combined with cataract surgery in open-angle glaucoma (OAG) patients. Retrospective, open-label study conducted on insufficiently controlled OAG patients, who underwent a PMS implant procedure with mitomyc...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	José M. Martínez-de-la-Casa, Federico Saenz-Francés, Laura Morales-Fernandez, Lucia Perucho, Carmen Mendez, Ana Fernandez-Vidal, Sofía Garcia-Saenz, Ruben Sanchez-Jean, Julian García-Feijoo
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/ca6b7575f3194d918dd5a6ed58e9ea49
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ca6b7575f3194d918dd5a6ed58e9ea49
record_format	dspace
spelling	oai:doaj.org-article:ca6b7575f3194d918dd5a6ed58e9ea492021-12-02T17:06:25ZClinical outcomes of combined Preserflo Microshunt implantation and cataract surgery in open-angle glaucoma patients10.1038/s41598-021-95217-x2045-2322https://doaj.org/article/ca6b7575f3194d918dd5a6ed58e9ea492021-08-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-95217-xhttps://doaj.org/toc/2045-2322Abstract To assess the effectiveness and safety of the Preserflo Microshunt (PMS) implantation combined with cataract surgery in open-angle glaucoma (OAG) patients. Retrospective, open-label study conducted on insufficiently controlled OAG patients, who underwent a PMS implant procedure with mitomycin-C 0.2%, either alone or in combination with cataract surgery, and were followed for at least 12 months. Success was defined as an intraocular pressure (IOP) ≤ 18 mmHg and a reduction of at least 20% without (complete) or with (qualified) hypotensive medication. Fifty-eight eyes were included in the study, 35 eyes underwent PMS alone and 23 underwent PMS + Phaco. In the overall study sample, mean IOP was significantly lowered from 21.5 ± 3.3 mmHg at baseline to 14.6 ± 3.5 mmHg at month 12 (p < 0.0001). The IOP was significantly reduced in both groups; p < 0.0001 each, respectively. Ocular hypotensive medication was significantly reduced (p < 0.0001) in both groups. No significant differences were observed in IOP lowering or medication reduction between groups. At month 12, 62.1% eyes were considered as complete success and 82.8% eyes as qualified success. The most common adverse events were device close-to-endothelium, conjunctival fibrosis, and wound leakage. PMS, either alone or in combination with phacoemulsification, may be considered as a valuable option for treating OAG patients.José M. Martínez-de-la-CasaFederico Saenz-FrancésLaura Morales-FernandezLucia PeruchoCarmen MendezAna Fernandez-VidalSofía Garcia-SaenzRuben Sanchez-JeanJulian García-FeijooNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-8 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q José M. Martínez-de-la-Casa Federico Saenz-Francés Laura Morales-Fernandez Lucia Perucho Carmen Mendez Ana Fernandez-Vidal Sofía Garcia-Saenz Ruben Sanchez-Jean Julian García-Feijoo Clinical outcomes of combined Preserflo Microshunt implantation and cataract surgery in open-angle glaucoma patients
description	Abstract To assess the effectiveness and safety of the Preserflo Microshunt (PMS) implantation combined with cataract surgery in open-angle glaucoma (OAG) patients. Retrospective, open-label study conducted on insufficiently controlled OAG patients, who underwent a PMS implant procedure with mitomycin-C 0.2%, either alone or in combination with cataract surgery, and were followed for at least 12 months. Success was defined as an intraocular pressure (IOP) ≤ 18 mmHg and a reduction of at least 20% without (complete) or with (qualified) hypotensive medication. Fifty-eight eyes were included in the study, 35 eyes underwent PMS alone and 23 underwent PMS + Phaco. In the overall study sample, mean IOP was significantly lowered from 21.5 ± 3.3 mmHg at baseline to 14.6 ± 3.5 mmHg at month 12 (p < 0.0001). The IOP was significantly reduced in both groups; p < 0.0001 each, respectively. Ocular hypotensive medication was significantly reduced (p < 0.0001) in both groups. No significant differences were observed in IOP lowering or medication reduction between groups. At month 12, 62.1% eyes were considered as complete success and 82.8% eyes as qualified success. The most common adverse events were device close-to-endothelium, conjunctival fibrosis, and wound leakage. PMS, either alone or in combination with phacoemulsification, may be considered as a valuable option for treating OAG patients.
format	article
author	José M. Martínez-de-la-Casa Federico Saenz-Francés Laura Morales-Fernandez Lucia Perucho Carmen Mendez Ana Fernandez-Vidal Sofía Garcia-Saenz Ruben Sanchez-Jean Julian García-Feijoo
author_facet	José M. Martínez-de-la-Casa Federico Saenz-Francés Laura Morales-Fernandez Lucia Perucho Carmen Mendez Ana Fernandez-Vidal Sofía Garcia-Saenz Ruben Sanchez-Jean Julian García-Feijoo
author_sort	José M. Martínez-de-la-Casa
title	Clinical outcomes of combined Preserflo Microshunt implantation and cataract surgery in open-angle glaucoma patients
title_short	Clinical outcomes of combined Preserflo Microshunt implantation and cataract surgery in open-angle glaucoma patients
title_full	Clinical outcomes of combined Preserflo Microshunt implantation and cataract surgery in open-angle glaucoma patients
title_fullStr	Clinical outcomes of combined Preserflo Microshunt implantation and cataract surgery in open-angle glaucoma patients
title_full_unstemmed	Clinical outcomes of combined Preserflo Microshunt implantation and cataract surgery in open-angle glaucoma patients
title_sort	clinical outcomes of combined preserflo microshunt implantation and cataract surgery in open-angle glaucoma patients
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/ca6b7575f3194d918dd5a6ed58e9ea49
work_keys_str_mv	AT josemmartinezdelacasa clinicaloutcomesofcombinedpreserflomicroshuntimplantationandcataractsurgeryinopenangleglaucomapatients AT federicosaenzfrances clinicaloutcomesofcombinedpreserflomicroshuntimplantationandcataractsurgeryinopenangleglaucomapatients AT lauramoralesfernandez clinicaloutcomesofcombinedpreserflomicroshuntimplantationandcataractsurgeryinopenangleglaucomapatients AT luciaperucho clinicaloutcomesofcombinedpreserflomicroshuntimplantationandcataractsurgeryinopenangleglaucomapatients AT carmenmendez clinicaloutcomesofcombinedpreserflomicroshuntimplantationandcataractsurgeryinopenangleglaucomapatients AT anafernandezvidal clinicaloutcomesofcombinedpreserflomicroshuntimplantationandcataractsurgeryinopenangleglaucomapatients AT sofiagarciasaenz clinicaloutcomesofcombinedpreserflomicroshuntimplantationandcataractsurgeryinopenangleglaucomapatients AT rubensanchezjean clinicaloutcomesofcombinedpreserflomicroshuntimplantationandcataractsurgeryinopenangleglaucomapatients AT juliangarciafeijoo clinicaloutcomesofcombinedpreserflomicroshuntimplantationandcataractsurgeryinopenangleglaucomapatients
_version_	1718381637892308992

Clinical outcomes of combined Preserflo Microshunt implantation and cataract surgery in open-angle glaucoma patients

Ejemplares similares